CGL’s Oncopanel is a next-generation sequencing assay that is offered to provide predictive, prognostic, and diagnostic information for patients with a variety of solid tumours. All the genes targeted by this assay (see below) are screened for DNA changes (variants).

Objective: - To report the development and validation of OncoPanel, a custom targeted next-generation sequencing assay for cancer. Design: - OncoPanel was designed for the detection of single-nucleotide variants, insertions and deletions, copy number alterations, and structural variants across 282 genes with evidence as drivers of cancer biology.

Onco Panscan（组织版）panel是覆盖肺癌、胃癌、肠癌、肝癌、甲状腺癌等中国前10大癌种的泛癌种大panel产品，其可实现多基因、多突变类型的一次性检测。 此次验证中，产品的准确性、检测限、精密度、干扰物质、稳定性均展现出优异的性能数据。

2021年8月11日 · 泛生子Onco PanScanTM基于“杂交捕获”和NGS测序技术，可综合评估靶向治疗、化疗、免疫治疗方案的有效性，精准指导肿瘤患者的个体化诊断和治疗，一次检测、全面获益。

NCOPANEL (POPv3) TEST INFORMATION BACKGROUND: Somatic genetic alterations in oncogenes and tumor-suppressor genes contribute to th. pathogenesis and evolution of human cancers. These alterations can provide prognostic and predictive information and stratify. cancers for targeted therapeutic information. We classify these alterations i.

This is a Next Generation Sequencing assay designed to interrogate over 1,200 solid tumor and hematological malignancy related genes via analysis of Peripheral Blood, Bone Marrow, Formalin-Fixed Paraffin-Embedded and Cytology Smear specimens. 28 additional genes were added to the previously 119 clinically reported genes.

The Solid Tumor HotSpot and Fusion OncoPanel is a custom-designed targeted RNA sequencing assay, created to detect gene fusions, exon skipping events, and select expressed hotspot mutations in solid tumors (see table 1 and 2 for gene lists). Selected gene targets represent recurrently altered genes expressed in solid tumors.

A ROBUST DRUG RESPONSE PLATFORM WITH CUSTOM OPTIONS TO DRIVE ONCOLOGY THERAPEUTIC DISCOVERY AND DEVELOPMENT, OFFERED EXCLUSIVELY BY Eurofins Discovery. Over 300 2D and 100 3D spheroid human cancer cell line models drive design of epigenetic, kinase, gene family, and target-focused expression panels, making thorough candidate assessment possible ...

Todai OncoPanel (TOP) is a dual DNA-RNA panel as well as a paired tumor-normal matched test. Two hundred patients underwent TOP as part of Advanced Medical Care B with approval from the Ministry of Health, Labour and Welfare between September 2018 and December 2019.

CGL’s Oncopanel is a next-generation sequencing assay that is offered to provide predictive, prognostic, and diagnostic information for patients with a variety of solid tumours. All the genes targeted by this assay are screened for DNA changes (variants).